Nacubactam is under clinical development by Meiji Seika Pharma and currently in Phase I for Pseudomonas aeruginosa Infections. According to GlobalData, Phase I drugs for Pseudomonas aeruginosa Infections have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nacubactam’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nacubactam (RG6080, RO7079901) is under development for the treatment of complicated urinary tract infections including pyelonephritis and gram-negative bacterial infections such as Pseudomonas aeruginosa infections,hospital acquired bacterial pneumonia, ventilator associated bacterial pneumonia and complicated intra-abdominal infections. The drug candidate is administered intravenously. It is a new molecular entity (NME) and a diazabicyclooctane beta-lactamase inhibitor.
Meiji Seika Pharma overview
Meiji Seika Pharma, a subsidiary of Meiji Holdings Co Ltd, is a pharmaceutical solutions provider. The company is engaged in providing pharmaceutical, veterinary drugs and chemicals used for agriculture. The company offers Streptomycin Meiji, Kanamycin Meiji, Habekacin, Orapenem, Reflex, Sycrest, Depromel and others. It operates manufacturing and development technologies, which provides a series of excellent antibacterial drugs. Meiji Seika Pharma also carries out research and development programs on infectious diseases and central nervous system disorders. The company offers products for human and veterinary care. It operates research centre, laboratories, and agricultural and veterinary research laboratories in Japan. Meiji Seika Pharma is headquartered in Tokyo, Japan.
For a complete picture of Nacubactam’s drug-specific PTSR and LoA scores, buy the report here.